A review of data involving 206 adults with chronic kidney disease looked at how iron chelators affect the body. The study focused on iron levels, blood markers, and potential side effects. The results showed that iron chelation led to a decrease in serum ferritin, transferrin, and serum iron. Additionally, patients saw an increase in hemoglobin levels.
While the treatment showed these positive changes in iron management, it did cause common gastrointestinal side effects. Serious adverse events were reported as rare. The study also noted that glucose levels decreased, while lipid parameters remained unaffected by the treatment.
It is important to note that this evidence is limited by small sample sizes and high variability between studies. Because the data is not yet definitive, more high-quality trials are needed to confirm how well this works for everyone. Patients should talk to their doctors to see if this treatment fits their specific needs.
